LHX — L3Harris Technologies, Inc.

As of 2026-09-13, the market is treating LHX as if earnings growth is at risk, driving shares to $245.54, below all key moving averages and down 15.6% in one month. This negative tape contrasts with the July 29 Q2 2026 beat, raised guidance, record $42B backlog, and the September $4.7B PAC-3 MSE propulsion contract. Despite a consensus Buy rating and analyst targets well above the current price, policy and governance concerns appear to be dominating the near-term narrative.

The 3-year quarterly trend shows an inflection rather than deterioration. Revenue growth re-accelerated in 2026: Q1 2026 +11.9% YoY and Q2 2026 +8.4% YoY, after mid-single-digit growth through most of 2025. Operating margin has stabilized around 11.1-11.2% in Q1/Q2 2026 versus roughly 10.8% in the prior-year quarters, although Q4 2025 was distorted by a sharp drop to 6.7% operating margin and $1.59 EPS, likely reflecting one-time charges. EPS has strengthened materially: Q2 2026 EPS of $3.13 versus $2.44 in Q2 2025 (+28%), and Q1 2026 EPS of $2.72 versus $2.04 (+33%). Free cash flow also rebounded, with Q2 2026 FCF of $771M versus $552M a year earlier, bringing TTM FCF to roughly $2.8B. This looks like an accelerating/improving trend with one messy quarter, not a structural decline.

As of 2026-09-13, LHX trades at 24.65x TTM EPS of $10.029 versus its 5-year average P/E of 31.09x. On the FY2027 consensus EPS estimate of $11.942, the forward P/E is about 20.6x. The trailing PEG of 2.285 looks high, but that uses trailing EPS; on forward growth from TTM EPS to the next-year estimate (~19%), the implied PEG is closer to 1.1. Price-to-sales is 1.994 versus a 5-year average of 2.26. The deterministic score labels the stock 'Cheap vs. its own history,' and that aligns with the current multiple compression despite improving fundamentals.

The market is pricing LHX as if forward earnings are vulnerable, but reported results show the opposite: Q2 2026 EPS beat consensus by roughly $0.33 and management raised full-year guidance, yet the stock fell 20% over three months. This is a classic 'good earnings, bad tape' setup. If the October 29 Q3 2026 report confirms the revenue acceleration and backlog conversion, the gap between price and earnings power should narrow. If the market is instead correctly pricing in government spending cuts or contract delays, the $11.942 forward EPS estimate could prove optimistic. Watch Q3 bookings and segment margin trajectory as the key tell.

As of 2026-09-13, RSI stood at 24.88, a deeply oversold reading. The stock was 7.1% below its 20-day SMA, 12.1% below its 50-day SMA, and 21.7% below its 200-day SMA, with a six-month return of -31.6%. This is a firm downtrend, but oversold extremes of this magnitude often precede at least a tactical bounce. For long-term investors, the technical washout may be an opportunity if fundamentals hold; for traders, waiting for RSI to reclaim 30-35 and price to close above the 20-day SMA would reduce the risk of catching a falling knife.

• U.S. defense budget and policy risk: potential government spending cuts, continuing resolutions, and efficiency initiatives could delay contract awards and cash conversion.
• Geopolitical tensions: persistent global security threats support demand for missile defense, electronic warfare, tactical communications, and space payloads.
• Interest rates: higher-for-longer rates pressure valuation multiples for long-duration defense cash flows and raise the cost of capital; rate cuts would be a tailwind.
• Sector rotation: defense has been a geopolitical safe-haven trade, but rotation into other sectors or de-rating of defense multiples could keep pressure on LHX shares.
• Supply chain and labor: aerospace and defense supply-chain constraints, skilled-labor shortages, and fixed-price contract inflation remain margin risks.

• Q3 2026 earnings on October 29, 2026, with updated guidance, backlog conversion, and margin commentary.
• The $4.7 billion PAC-3 MSE propulsion contract from Lockheed Martin announced in September 2026, ramping over multiple years.
• Record $42 billion backlog and 1.2x book-to-bill in Q2 2026; further order awards could reinforce the growth narrative.
• Management presentations at investor conferences, including the Morgan Stanley Laguna Conference in mid-September 2026.
• Potential clarity on U.S. defense budget negotiations and resolution of governance/executive-transition investigations.

• U.S. government budget cuts, continuing resolutions, or shifting procurement priorities could delay orders and cash flow.
• Margin pressure from fixed-price contracts, supply-chain inflation, and one-time charges, as seen in Q4 2025 when operating margin fell to 6.7%.
• Governance scrutiny and investigations following executive transition events could weigh on valuation multiples.
• Execution risk on converting the record $42 billion backlog into revenue and profit at expected margins.
• Valuation multiple compression if the defense sector de-rates or if interest rates rise further.

At $245.54 as of 2026-09-13, LHX presents a compelling disconnect: operating fundamentals are improving with Q2 revenue up 8.4%, EPS up 28%, record $42B backlog, a $4.7B PAC-3 award, and TTM FCF near $2.8B, while the stock sits near a 52-week low and trades at just ~20.6x forward EPS versus a 31.1x 5-year average. I view this as a value opportunity rather than a broken business, but the weak technicals and unresolved policy/governance risks mean patient investors should expect volatility and watch for confirmation in the Q3 report.

Applied a 23.5x multiple to the FY2027 consensus EPS estimate of $11.942, which is a discount to LHX's 5-year average P/E of 31.1x but a premium to its current forward P/E of roughly 20.6x, justified by accelerating revenue, record backlog, and strong free cash flow. 11.942 × 23.5 = $280.64.